Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.32 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.32 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.32 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | EYA2 | O00167 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27413038 | 0.98 | — | — | |
| SCHEMBL27442260 | 0.76 | LMNA (0.33) | KDM4ELMNATSHRBLM | |
| SCHEMBL447116 | 0.73 | — | — | |
| SCHEMBL2192119 | 0.73 | — | — | |
| Water SCHEMBL4457971 | 0.71 | TDP1 (0.32) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL8047672 | 0.70 | — | — | |
| SCHEMBL8076843 | 0.69 | — | — | |
| SCHEMBL18658740 | 0.65 | TDP1 (0.35) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL1630009 | 0.63 | TDP1 (0.47) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL2102764 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | claimed |
| US-5994577-A | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | PHARMACIA & UPJOHN COMPANY | 1999-11-30 | — | — | US | claimed |
| US-20020082448-A1 | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | THE UPJOHN COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-6329545-B1 | SYSTEMIC ADMINISTRATION OF .ALPHA.-((AMINOIMINOMETHYL)HYDRAZONO)-BENZENEPROPANOIC ACID OR ITS HYDROCHLORIDE SALT FOR THERAPY OF DIABETES | LARSEN SCOTT D (US) | 2001-12-11 | — | — | US | disclosed |
| EP-0793646-B1 | AMINOGUANIDINE CARBOXYLATES FOR THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS | UPJOHN CO (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6166080-A | Aminoquanidine carboxylates for the treatment of obesity | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-5994577-A | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | PHARMACIA & UPJOHN COMPANY | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082448-A1 | Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus | GPR119, IAPP, SLC5A2 | CHRM2 649/4885ADRA2A 1041/4885SLC6A2 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.